Akzo reiterates top 20 target in pharma

14 May 2001

Akzo Nobel says it is looking to post 2001 net profit, excludingextraordinary items, of around the same level as last year, ie 950 million euros ($845.5 million), "despite facing a tougher economic climate," according to chief executive Cees van Lede. He added that the group's pharmaceuticals division, based on the "three strong pillars" of Organon, Diosynth and Intervet, should maintain double-digit growth and said that Akzo's aim is to break into the top 20 rankings of drugmakers.

Xyvion US launch delayed for two years

However, the company had some bad news to relate connected with the launch of its osteoporosis drug Xyvion (tibolone) in the USA, which will be delayed by two years because it needs additional clinical research. The drug recently received US Food and Drug Administration approval (Marketletter May 7), but Akzo says it is not satisfied with the approved labeling. Tibolone is sold in the UK as Livial and is marketed in 70 other countries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight